SCHEMBL26506559

SCHEMBL26506559

COC(=O)c1ccccc1Oc1nc(Nc2ccc(OC(F)F)cc2)ncc1Br

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 4/20 0.54
▸ PRKAA2 P54646 1/20 0.54
▸ PRKAA1 Q13131 1/20 0.54
▸ ULK2 Q8IYT8 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ TEAD4 Q15561 1/20 0.43
▸ EGFR P00533 3/20 0.43
▸ CHEK1 O14757 1/20 0.42
▸ NTRK2 Q16620 1/20 0.42
▸ CDK2 P24941 4/20 0.42
▸ CDK1 P06493 3/20 0.42
▸ KDR P35968 3/20 0.42
▸ CCNB1 P14635 2/20 0.42
▸ CCNE1 P24864 2/20 0.42
▸ GRM5 P41594 1/20 0.42
▸ PTK2 Q05397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26506566 0.91 ULK1 (0.55) ULK1PRKAA2PRKAA1ULK2MEN1
SCHEMBL26506551 0.89 ULK1 (0.61) ULK1PRKAA2PRKAA1ULK2SMN1; SMN2
SCHEMBL26506543 0.87 ULK1 (0.55) ULK1PRKAA2PRKAA1ULK2MEN1
SCHEMBL26506579 0.86 ULK1 (0.59) ULK1PRKAA2PRKAA1ULK2MEN1
SCHEMBL26506589 0.86 ULK1 (0.59) ULK1PRKAA2PRKAA1ULK2MEN1
SCHEMBL26506580 0.85 ULK1 (0.58) ULK1PRKAA2PRKAA1ULK2MEN1
SCHEMBL26506588 0.84 ULK1 (0.55) ULK1PRKAA2PRKAA1ULK2SMN1; SMN2
SCHEMBL26506586 0.83 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2MEN1
SCHEMBL26506572 0.83 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2MEN1
SCHEMBL26506581 0.83 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME ULK2, ULK1, ULK3 ULK1 2/4885PRKAA2 130/4885PRKAA1 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback